AVROBIO (AVRO)
(Delayed Data from NSDQ)
$1.39 USD
0.00 (0.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.40 +0.01 (0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
AVROBIO, Inc. [AVRO]
Reports for Purchase
Showing records 41 - 60 ( 114 total )
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
What Does the FDA Have to Say about Fabry Study?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Ready to Shake the WORLDSymposium with Updates in Fabry & Gaucher
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
New Programs and Program Updates at R-D Day November 17th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Slow Going for Programs Leveraged on Busulfan-Based Lymphodepletion
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D